SciSparc Ltd.的合作方Neurothera Labs宣布,其与Clearmind Medicine共同开发的一项针对减重及脂肪肝疾病的新型疗法国际专利已正式公布。该专利标志着双方在代谢疾病治疗领域的合作取得重要进展,为开发创新疗法奠定了坚实基础。
SciSparc Ltd.的合作方Neurothera Labs宣布,其与Clearmind Medicine共同开发的一项针对减重及脂肪肝疾病的新型疗法国际专利已正式公布。该专利标志着双方在代谢疾病治疗领域的合作取得重要进展,为开发创新疗法奠定了坚实基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.